Skip to main content

Advertisement

SpringerLink
Log in

Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management

  • Case Report
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

Pregnancy-associated atypical hemolytic uremic syndrome is a systemic disease associated with high morbidity and mortality rates, caused by dysregulation of the alternative complement pathway, leading to uncontrolled complement activation resulting in thrombotic microangiopathy. This condition can be effectively treated by anti-C5 therapy, which controls complement activation. Treatment can be safely discontinued after complete remission and resolution of the precipitating cause, especially in patients with a low-risk genetic profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dashe JS, Ramin SM, Cunningham FG (1998) The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol 91:662–668

    Article  CAS  PubMed  Google Scholar 

  2. Fakhouri F, Roumenina L, Provot F et al (2010) Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21:859–867

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Faguer S, Huart A, Frémeaux-Bacchi V, Ribes D, Chauveau D (2013) Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 6:484–485

    Article  PubMed Central  PubMed  Google Scholar 

  4. Delmas Y, Bordes C, Loirat C, Frémeaux-Bacchi V, Combel C (2013) Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 6:243–244

    Article  PubMed Central  PubMed  Google Scholar 

  5. Cañigral C, Moscardó F, Castro C et al (2014) Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol 93:1421–1422

    PubMed  Google Scholar 

  6. Ardissino G, Wally OM, Maria BG, Rigotti A, Cugno M (2013) Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 122(2 Pt 2):487–489

    Article  PubMed  Google Scholar 

  7. Zschiedrich S, Prager EP, Kuehn EW (2013) Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann Intern Med 2(159):76

    Article  Google Scholar 

  8. Kourouklaris A, Ioannou K, Athanasiou I et al (2014) Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J Med Case Rep 8:307

    Article  PubMed Central  PubMed  Google Scholar 

  9. Robson JS, Martin AM, Ruckley VA, MacDonald MK (1968) Irreversible post partum renal failure. A new syndrome. QJ Med 37:423

    CAS  Google Scholar 

  10. Loirat C, Frémeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 6:60

    Article  PubMed Central  PubMed  Google Scholar 

  11. Anacleto FE, Cifra CL, Elises JS (2003) Postpartum hemolytic uremic syndrome in a 17-year-old Filipina primigravid. Pediatr Nephrol 18:1283–1285

    Article  PubMed  Google Scholar 

  12. McMinn JR, George JN (2001) Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apher. 16:202–209

    Article  CAS  PubMed  Google Scholar 

  13. George JN (2003) The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Curr Opin Hematol 10:339–344

    Article  PubMed  Google Scholar 

  14. George JN (2000) How I treat patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Blood 86:1223–1229

    Google Scholar 

  15. Bresin E, Rurali E, Caprioli J et al (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475–486

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Ardissino G, Testa S, Possenti I et al (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64:633–637

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Dr. E. De Sousa acts as a scientific advisor for Alexion Pharmaceuticals. Dr. Campistol, Dr. Rodriguez de Cordoba and Mr. Blasco have received fees from Alexion Pharmaceuticals for invited lectures. The other authors declare that they have no relevant conflicts of interest.

Ethical standard

The present study was performed in accordance with the ethical standards of the institutional research committee and with the Helsinki declaration.

Informed consent

Written consent was obtained from the patient discussed and documentation is available for review upon request.

Author information

Authors and Affiliations

  1. Nephrology Department, Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain

    Erika De Sousa Amorim, Miquel Blasco, Luis Quintana & Josep Maria Campistol

  2. Histopathology Department, Hospital Clinic, Barcelona, Spain

    Manel Sole

  3. Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 28040, Madrid, Spain

    Santiago Rodríguez de Cordoba

Authors
  1. Erika De Sousa Amorim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miquel Blasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luis Quintana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manel Sole
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Santiago Rodríguez de Cordoba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Josep Maria Campistol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erika De Sousa Amorim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Sousa Amorim, E., Blasco, M., Quintana, L. et al. Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 28, 641–645 (2015). https://doi.org/10.1007/s40620-015-0173-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-015-0173-5

Keywords

Search

Navigation